Half-year report · HY
4564.TEDINET S100X054
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥432m | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥225m | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | −¥476m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥531m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | −¥494m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥554m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥545m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥555m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥546m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥289m | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥426m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥834m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥834m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥525m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥579m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥61m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥279,000 | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.89 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.18 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥185,000 |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥185m |
| Cancer Precision Medical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥430m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥7m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥284m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥432m |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥185,000 |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | −¥291m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥135,000 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥178m |
| Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥222m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥94m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥259m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥225m |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥135,000 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | −¥353m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 400
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 2970000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 222113000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 225083000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 225083000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 135000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 135000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -135000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 3105000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 222113000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 225219000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -135000 | JPY |
| Net sales | Prior1InterimDuration | 225083000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -259122000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -93553000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | -352676000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -178441000 | JPY |
| Operating income | Prior1InterimDuration | -531117000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 2330000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 429561000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 431891000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 431891000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 185000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 185000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -185000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 2515000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 429561000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 432076000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -185000 | JPY |
| Net sales | InterimDuration | 431891000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -283917000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -6598000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | -290515000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | -185423000 | JPY |
| Operating income | InterimDuration | -475938000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-10 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第25期中（自 2025年４月１日 至 2025年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)オンコセラピー・サイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | OncoTherapy Science, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 嶋田 順一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県川崎市川崎区東田町１番地２ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 044－201－6429 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |